Levovir
(Clevudine)Phase 3Small molecule
Clevudine is used to treat chronic hepatitis B, a viral infection that affects the liver. It works by slowing down the virus's ability to reproduce.[1] Levovir is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Levovir is one of 182 small molecule programs targeting Viral Disease. It is currently in Phase 3.
6
Indications
23
Total Trials
0
Active Trials
181
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Levovir
BBukwang Pharmaceutical
Phase 3
Spikevax
ModernaPreclinical
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis8 trials
Show 5 more trials
Safety and Efficacy4 trials
Chronic3 trials
Efficacy and Safety2 trials
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Clevudine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Protein P Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBukwang Pharmaceutical